| Literature DB >> 23034406 |
Adrienne Sevin1, Adrienne Chen, Brad Atkinson.
Abstract
Sorafenib and sunitinib are oral tyrosine kinase inhibitors, commonly used in the treatment of metastatic renal cell carcinoma. Known adverse events associated with tyrosine kinase inhibitors include hypertension and palmarplantar erythrodysesthesia. We report two cases of acute pancreatitis associated with tyrosine kinase inhibitors.Entities:
Keywords: Pancreatitis; sorafenib; sunitinib; tyrosine kinase inhibitor
Mesh：
Substances：
Year: 2012 PMID： 23034406 DOI： 10.1177/1078155212457968
Source DB: PubMed Journal: J Oncol Pharm Pract ISSN： 1078-1552 Impact factor: 1.809